在急性呼吸窘迫综合征中,CLCA1通过p38 MAPK通路加剧肺炎
Xing Lv1, Long Zheng1, Tianxiang Zhang2
1Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Experimental lung research
|April 10, 2024
概括
空气道上皮质激活化物通道-1 (CLCA1) 在急性呼吸困扰综合征 (ARDS) 中升高,通过p38 MAPK通路恶化肺损伤和炎症. 减少CLCA1表达或p38激活可以缓解ARDS症状.
科学领域:
- 肺部医学 肺部医学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 空气道上皮质活化化通道-1 (CLCA1) 与呼吸道疾病炎症有关.
- 目前尚不清楚CLCA1在急性呼吸窘迫综合征 (ARDS) 中的具体作用.
研究的目的:
- 研究CLCA1在ARDS病变发生过程中的作用和机制.
主要方法:
- 人类研究:80名参与者 (26 ARDS,26社区获得的肺炎,28对照).
- 动物模型:脂聚糖 (LPS) 诱导的ARDS小鼠模型.
- 分析:CLCA1水平,中性粒细胞透,BALF蛋白,炎症因素,p38 MAPK酸化.
主要成果:
- 在ARDS患者中,CLCA1水平显著增加,与中性粒细胞透和预后不佳相关.
- 在LPS诱导的ARDS小鼠模型中,CLCA1水平升高.
- 在小鼠中,CLCA1的使用使ARDS表型恶化,而CLCA1抑制或p38抑制缓解了炎症.
- CLCA1改变了p38的酸化,这表明它参与了p38 MAPK路径.
结论:
- CLCA1与ARDS有显著的相关性,并加剧了ARDS表型.
- 这种p38 MAPK通路参与了CLCA1介导的ARDS病变发生.
- CLCA1代表了ARDS的潜在治疗点.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:07MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K